Sarcoidosis and diabetes can occur together, and corticosteroids may raise blood-glucose levels. Symptoms such as thirst, frequent urination, blurred vision or unusual fatigue should be discussed with a clinician. Monitoring and treatment may need adjustment during illness or steroid therapy. Never change diabetes or sarcoidosis medicines without a coordinated medical plan.
Risk of type 2 diabetes in patients with sarcoidosis
The Swedish study described below examined the risk of diabetes in people with untreated sarcoidosis and in those treated with corticosteroids, whose role in the development of diabetes was not yet fully clarified.
Glucocorticoids can raise blood-sugar levels very quickly in some patients, particularly older men. The source notes that it is not fully understood why this could lead to chronic type 2 diabetes in some people.
Read the article:
Risk of type 2 diabetes in patients with untreated and corticosteroid-treated sarcoidosis
Abstract
Background: The rate of type 2 diabetes mellitus (T2D) is increased in patients with sarcoidosis, but it is not known whether corticosteroid treatment plays a role. The researchers investigated whether T2D risk was higher in untreated and corticosteroid-treated patients with sarcoidosis than in the general population.
Methods: In this cohort study, individuals with two or more International Statistical Classification of Diseases and Related Health Problems (ICD) codes for sarcoidosis were identified in the Swedish National Patient Register (NPR) (n=5754). Corticosteroid dispensations within 3 months before or after the first sarcoidosis diagnosis were identified in the Swedish Prescribed Drug Register (PDR). General-population comparators without sarcoidosis were matched to cases 10:1 by age, sex and region of residence (n=61 297). Incident T2D was identified using ICD codes (NPR) and dispensations of antidiabetic medicines (PDR). Follow-up ran from the second sarcoidosis diagnosis or corresponding matched date until T2D, emigration, death or the end of the study in December 2013. Cox regression models adjusted for age, sex, education, country of birth, healthcare region and family history of diabetes were used to estimate hazard ratios (HR). Flexible parametric models were used to examine T2D risk over time.
Results: At diagnosis, 40% of patients with sarcoidosis were treated with corticosteroids. The T2D rate was 7.7 per 1000 person-years in untreated sarcoidosis, 12.7 per 1000 person-years in corticosteroid-treated sarcoidosis and 5.5 per 1000 person-years in the comparators. The HR for T2D was 1.4 (95% CI 1.2–1.8) in association with untreated sarcoidosis and 2.3 (95% CI 2.0–3.0) in association with corticosteroid-treated sarcoidosis. T2D risk was highest in corticosteroid-treated sarcoidosis during the first 2 years after diagnosis.
Conclusions: The study associated sarcoidosis with an increased risk of T2D, particularly in older patients, men and patients treated with corticosteroids at diagnosis. Its authors recommended screening these patients for T2D.
Source: https://pubmed.ncbi.nlm.nih.gov/34046487/